LeAnne Kennedy, PharmD, BCOP, CPP, FHOPA, FASTCT, discusses the collaborative culture, research opportunities, and leadership pathways that define oncology pharmacy practice at Atrium Health Wake Forest Baptist, while emphasizing the importance of advocacy and visibility for the profession.
Sundar Jagannath, MD, MBBS, discusses how linvoseltamab’s streamlined step-up dosing and REMS program support broader use in community settings and improved tolerability for older patients.
Pre-treatment DPYD genotyping significantly reduces hospitalizations and costs for patients with cancer, enhancing safety and efficiency in oncology care.
Grace Nguyen, PharmD, BCPS, provides real-world experiences with DPYD genotype-guided fluoropyrimidine dosing, highlighting how pharmacist-led interventions and tailored dose adjustments can help mitigate toxicity risks and optimize treatment in variant carriers.
Don Moore, PharmD, BCPS, BCOP, DPLA, FCCP, FASHP, received a leadership award at the 2025 HOPA Annual Meeting.
Arefa Bacchus, PharmD, shared key insights about the use of POMP therapy in patients with acute lymphoblastic leukemia (ALL).
Monica Sawiris, PharmD, said there were noticeable differences in toxicities between each regimen.
Jessica Davis, PharmD, BCOP highlights the role of pharmacy technicians in ambulatory oncology clinic settings.
Julia Ziegengeist, PharmD, BCOP offers insights for pharmacists navigating adjuvant and neoadjuvant treatment of breast cancer.
Alexandra Wolff, PharmD, BCOP, FHOPA, was awarded a fellow of HOPA at the 2025 annual meeting.
Michael Arnold, PharmD, discussed the role of oncology pharmacists in enhancing biomarker testing for patients with metastatic colorectal cancer.
Pharmacists identify appropriate patients for new oral and antibody drug conjugate treatments and provide counseling to help patients navigate the evolving treatment landscape.
Donald Moore discusses some of the obstacles that bispecific antibodies have faced in community cancer centers, including misconceptions coupled with a prevalent toxicity profile.
Jai N. Patel, PharmD, BCOP, CPP, discussed efforts to standardize the evaluation of clinical utility in pharmacogenetics, emphasizing its variability, the role of pharmacogenomics in research, and the importance of robust study designs for pharmacy professionals.
Brigimadlin is a new oral MDM2-p53 antagonist under investigation as a potential first-line therapy to improve outcomes for patients with advanced or metastatic dedifferentiated liposarcoma.
HER2-mutant NSCLC is associated with poor prognosis. Zongertinib and BAY 2927088 are HER2 tyrosine kinase inhibitors that have activity in NSCLC with manageable toxicity profiles.
